| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/25/2000 | WO2000019988A8 NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF |
| 05/25/2000 | WO2000018428A3 Hedgehog and patched antagonists for inhibiting cell and tissue growth and differentiation and uses therefor |
| 05/25/2000 | WO2000018385A3 Use of acylcarnitines as antitumour agents |
| 05/25/2000 | WO2000018254A3 Method of protecting heat- or oxygen-labile compounds to preserve activity and bioavailability |
| 05/25/2000 | WO2000017233A3 Genes of the 1-desoxy-d-xylulose biosynthetic pathway |
| 05/25/2000 | WO2000016797A3 Use of glp-1 or analogs in treatment of stroke |
| 05/25/2000 | WO2000015798A3 Mammalian transforming growth factor beta - 9 (ztgfss9) |
| 05/25/2000 | WO2000015788A3 Dna sequence encoding oncofetal ferritin protein |
| 05/25/2000 | WO2000015247A3 Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
| 05/25/2000 | WO2000015210A3 Use of mycophenol acid and its derivatives for the treatment of virus diseases |
| 05/25/2000 | WO2000015209A3 REGULATION OF HER2/neu ONCONGENE EXPRESSION BY SYNTHETIC POLYAMIDES |
| 05/25/2000 | WO2000014228A8 Neutral amino acid transporter and gene thereof |
| 05/25/2000 | WO2000012690A3 Laminin 5 for treatment of bone defects |
| 05/25/2000 | WO2000012111A3 Selective treatment of endothelial somatostatin receptors |
| 05/25/2000 | WO2000012049A3 A method for the treatment of staphylococcal disease |
| 05/25/2000 | WO2000010595A3 Medicaments for manipulating t-cell immune response |
| 05/25/2000 | WO2000009543A3 Hepatitis c inhibitor tri-peptides |
| 05/25/2000 | WO2000009148A9 Vascular endothelial growth factor 3 |
| 05/25/2000 | WO2000008153A3 Arf-p19, a novel regulator of the mammalian cell cycle |
| 05/25/2000 | WO2000007545A8 Apoptosis proteins |
| 05/25/2000 | WO2000004051A3 Growth differentiation factor promoter and uses therefor |
| 05/25/2000 | WO2000002576A9 Egf-genistein for prevention of restenosis |
| 05/25/2000 | WO2000001801A9 Ftsz multimeric proteins and their uses |
| 05/25/2000 | WO2000001410A9 Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis |
| 05/25/2000 | WO1999053949A9 Combination of antigen pulsed apcs and interleukin 12 for tumor and viral therapy |
| 05/25/2000 | WO1999053939A9 Treatment of osteoporosis with leptin |
| 05/25/2000 | WO1999051762A9 Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders |
| 05/25/2000 | WO1999026644A9 Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
| 05/25/2000 | DE19853033A1 Stabilized factor XIII and fibrinogen preparations useful as tissue adhesive components |
| 05/25/2000 | DE19850986A1 Die gentechnische Prägung von Zellen und ihre Verwendung zur Prophylaxe und Therapie von Erkrankungen The genetic imprint of cells and their use in the prophylaxis and treatment of diseases |
| 05/25/2000 | DE19844022C1 Use of iron-binding glycoproteins and/or 10-hydroxy-2-decenoic acid in combination with thymoquinone for treating immunodeficiency diseases |
| 05/25/2000 | DE19840263C1 Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen Papillomaviruses means for their detection as well as for the treatment of diseases caused by them |
| 05/25/2000 | CA2356926A1 Methioninase gene therapy for tumor treatment |
| 05/25/2000 | CA2351874A1 G protein-coupled receptor resembling the leukotriene b4 receptor |
| 05/25/2000 | CA2351637A1 Recombinant glycoproteins, method for the production thereof, medicaments containing said glycoproteins and use thereof |
| 05/25/2000 | CA2351622A1 Polypeptide |
| 05/25/2000 | CA2351585A1 Influencing of angigenesis using cd66a |
| 05/25/2000 | CA2351576A1 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 05/25/2000 | CA2351524A1 12-25-kda bacterial proteins and their 116-58 kda polymers for use e.g. in anti-tumour vaccines |
| 05/25/2000 | CA2351522A1 Egf-like nucleic acids and polypeptides and uses thereof |
| 05/25/2000 | CA2351313A1 Immunoglobulin superfamily proteins |
| 05/25/2000 | CA2351170A1 Humanized antibody specific for human 4-1bb and pharmaceutical composition comprising same |
| 05/25/2000 | CA2351161A1 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 05/25/2000 | CA2351146A1 The cxc chemokine h174 and methods for preventing damage to the nervous system |
| 05/25/2000 | CA2351067A1 Method of treating heparin-induced thrombocytopenia |
| 05/25/2000 | CA2350917A1 Contraceptive antibody vaccines |
| 05/25/2000 | CA2350914A1 Treatment of tumors by administration of growth hormone releasing compounds and their antagonists |
| 05/25/2000 | CA2350911A1 Hiv-specific t-cell induction |
| 05/25/2000 | CA2350830A1 Hypoxia-inducible factor 1.alpha. hif-1.alpha. variants and methods for identifying hif-1.alpha. modulators |
| 05/25/2000 | CA2350785A1 31 human secreted proteins |
| 05/25/2000 | CA2350782A1 Compositions and methods for controlling plant pests |
| 05/25/2000 | CA2350501A1 Calcium fortified juice-based nutritional supplement |
| 05/25/2000 | CA2350415A1 Inflammation-associated genes |
| 05/25/2000 | CA2350391A1 Method for inhibiting macrophage infiltration using monoclonal anti-alpha-d-antibodies |
| 05/25/2000 | CA2350389A1 Calcium binding protein |
| 05/25/2000 | CA2349869A1 Novel protein and utilization thereof |
| 05/25/2000 | CA2349837A1 Lysozyme fusion proteins in infections |
| 05/25/2000 | CA2349762A1 Human tslp dna and polypeptides |
| 05/25/2000 | CA2349581A1 Anti-icam-r antibody-induced apoptosis |
| 05/25/2000 | CA2349238A1 Systemic viral/ligand gene delivery system and gene therapy |
| 05/25/2000 | CA2348824A1 12 human secreted proteins |
| 05/25/2000 | CA2348781A1 Compositions and methods for producing vascular occlusion |
| 05/25/2000 | CA2348676A1 Method for preparing (2s)-1-¬ (2r,3s)-5- chloro-3-(2- chlorophenyl) -1-(3,4-dimethoxy benzenesulphonyl) -3-hydroxy-2, 3-dihydro-1h- indole-2-carbonyl| pyrrolidine-2- carboxamide |
| 05/25/2000 | CA2347833A1 Antibody variants with higher binding affinity compared to parent antibodies |
| 05/25/2000 | CA2340468A1 Methods of facilitating vascular growth |
| 05/25/2000 | CA2317919A1 Cosmetic or dermatological use of 7-hydroxylated steroids alone and/or in combination with elastin derived peptides |
| 05/24/2000 | EP1002870A1 Androgen- and progesteron-receptor binding Hormone Response Element |
| 05/24/2000 | EP1002865A1 Adipose specific protein |
| 05/24/2000 | EP1002864A1 HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections |
| 05/24/2000 | EP1002863A1 A potassium channel member of the erg family |
| 05/24/2000 | EP1002862A1 Methods of diagnosing or treating neurological diseases |
| 05/24/2000 | EP1002803A1 Method for the isolation of legume lectins and their use as a medicament |
| 05/24/2000 | EP1002802A1 Dipeptide derivatives as growth hormone secretagogues |
| 05/24/2000 | EP1002556A2 Use of MMP inhibitors |
| 05/24/2000 | EP1002547A1 Hydrosoluble hedgehog protein in ionic complex and pharmaceutical use thereof |
| 05/24/2000 | EP1002543A1 Pharmaceutical compositions for the therapy of glioma or prostate cell proliferative disorders containing cyclic rgd compounds |
| 05/24/2000 | EP1002542A1 Method for treating the endotoxic shock in mammals |
| 05/24/2000 | EP1002534A1 Bis-Staurosporine and K-252a derivatives |
| 05/24/2000 | EP1002529A1 Sustained-release preparation containing a metal salt of a peptide |
| 05/24/2000 | EP1002132A1 90 human secreted proteins |
| 05/24/2000 | EP1002108A2 Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment |
| 05/24/2000 | EP1002106A1 Production and use of recombinant protein multimers with altered biological activity |
| 05/24/2000 | EP1002104A1 Novel metalloprotease |
| 05/24/2000 | EP1002101A2 Antifreeze proteins, dna and expression systems |
| 05/24/2000 | EP1002099A1 Synaptojanin isoform |
| 05/24/2000 | EP1002093A1 Preparation and use of recombinant influenza a virus m2 constructs and vaccines |
| 05/24/2000 | EP1002092A1 Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof |
| 05/24/2000 | EP1002084A1 Mammalian cytokine: interleukin-b30 and related reagents |
| 05/24/2000 | EP1002083A1 Aprotinin variants with improved properties and bikunins of aprotinin variants |
| 05/24/2000 | EP1002082A2 Transcriptional silencer protein nrf |
| 05/24/2000 | EP1002081A2 Delayed progression to aids by a missense allele of the ccr2 gene |
| 05/24/2000 | EP1002079A2 Novel inhibitor of cellular proliferation |
| 05/24/2000 | EP1002078A1 Method enabling readministration of aav vector via immunosuppresion of host |
| 05/24/2000 | EP1002077A1 Secreted proteins encoded by human chromosome 13 |
| 05/24/2000 | EP1002076A1 Proteins mediating switch recombination |
| 05/24/2000 | EP1002075A1 Adipocyte-specific protein homologs |
| 05/24/2000 | EP1002074A1 Calcium-binding phosphoprotein |
| 05/24/2000 | EP1002072A1 Human semaphorin e and polynucleotides encoding it |
| 05/24/2000 | EP1002071A1 Human glial cell line-derived neurotrophic factor promoters, vectors containing same, and methods of screening compounds therewith |
| 05/24/2000 | EP1002070A1 Human atp-binding cassette transport protein |